The funding will enable Mirna to advance its lead microRNA (miRNA) therapeutic product candidate, MRX34, into Phase 1b and Phase 2 trials in 2016. Indications for further development will be selected at the completion of Mirna's ongoing Phase 1 trial in patients with hepatocellular carcinoma, other solid tumors and hematological malignancies. The Company also plans to advance a second miRNA therapeutic candidate into clinical trials with the proceeds of this financing, as well as embark on a combination therapy development program.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

2150 Woodward St. 100
Austin, TX 78744
USA

Phone

(512) 901-0900

Website

www.mirnatherapeutics.com

Email Address

[email protected]

Overview

Mirna Therapeutics, Inc. (NASDAQ: MIRN) is a biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer.

Profile

Social Media

Mirna Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Paul Lammers

Chief Financial Officer

Alan Fuhrman

Chief Scientific Officer

Miguel Barbosa

VP - Finance

Jon Irvin

VP - R & D

Jay Stoudemire

Browse more venture capital transactions:

Prev: 4/30/2015: Sticky venture capital transaction
Next: 4/30/2015: Hedgy venture capital transaction

Share this article

News on VC Transactions

We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary